{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '12.', 'REFERENCES', 'Bykerk VP, \u00d6st\u00f6r AJK, Alvaro-Gracia J, Pavelka K, Ivorra JAR, Graninger W, et al.', 'Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to', 'DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann', 'Rheum Dis 2012;71:1950-1954.', 'Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, et al. Unresolved', 'issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing', 'the evidence. J Rheumatol Suppl 2008;81:4-30', 'Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of', 'patients with rheumatoid arthritis who switch to infliximab after an incomplete response to', 'etanercept: the opposite study. Ann Rheum Dis 2007;66:893-899.', 'Humira R (adalimumab) Prescribing Information, 2015', 'http://www.rxabbvie.com/pdf/humira.pdf', 'Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment', 'with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis', '2007;66:670-675.', 'Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha', 'antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions', 'of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-846.', 'Nelson WB. Recurrent events data analysis for product repairs, disease recurrences, and', 'other applications. SIAM, 2003.', 'Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing', 'initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11 (Suppl S1.', 'Sahai H, Khurshid A. Confidence intervals for the mean of a Poisson distribution: a review.', 'Biometrical J 1993;35(7):857-867.', 'Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al.', 'Second symposium on the definition and management of anaphylaxis: summary', 'report--Second National Institute of Allergy and Infectious Disease/Food Allergy and', 'Anaphylaxis Network symposium. J Allergy Clin Immunol 2006 Feb; 117(2):391-397.', 'Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The', '6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent', 'Amendment 2: 06 March 2019', '142', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept:', 'the ARRIVE trial. Ann Rheum Dis 2009;68:1708-1714', 'Siddiqui O. Statistical methods to analyze adverse events data of randomized clinical trials.', 'J Biopharm Stat 2009;19(5):889-899.', 'Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR', 'recommendations for the management of rheumatoid arthritis with synthetic and biological', 'disease-modifying antirheumatic drugs: 2013 updated. Ann Rheum Dis 2014;73:492-509.', 'Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and', 'efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis', 'in open-label, longterm extension studies. J Rheumatol 2014;41(5): 837-852.', 'World Health Organization. Global Tuberculosis Report 2015. Accessed on', '14 December 2015. Available from: http://www.who.int/tb/publications/global_report/en', 'Amendment 2: 06 March 2019', '143', 'Confidential']\n\n###\n\n", "completion": "END"}